Aldezole may be available in the countries listed below.
Ingredient matches for Aldezole
Metronidazole
Metronidazole is reported as an ingredient of Aldezole in the following countries:
- Myanmar
International Drug Name Search
Monday, 9 August 2010
Obenix
Generic Name: phentermine (FEN ter meen)
Brand Names: Adipex-P, Oby-Cap, T-Diet, Zantryl
What is Obenix (phentermine)?
Phentermine is a stimulant that is similar to an amphetamine. Phentermine is an appetite suppressant that affects the central nervous system.
Phentermine is used togther with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol, or diabetes.
Phentermine may also be used for other purposes not listed in this medication guide.
What is the most important information I should know about Obenix (phentermine)?
Taking phentermine together with other diet medications such as fenfluramine (Phen-Fen) or dexfenfluramine (Redux) can cause a rare fatal lung disorder called pulmonary hypertension. Do not take phentermine with any other diet medications without your doctor's advice.
Phentermine may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of phentermine.
Phentermine is only part of a complete program of treatment that may also include diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.
Phentermine may be habit-forming and should be used only by the person it was prescribed for. Never share phentermine with another person, especially someone with a history of drug abuse or addiction. Keep track of the amount of medicine used from each new bottle. Phentermine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription. Do not stop using phentermine suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using phentermine.
What should I discuss with my healthcare provider before taking Obenix (phentermine)?
Do not use phentermine if you have taken an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) in the last 14 days. Serious, life threatening side effects can occur if you use phentermine before the MAO inhibitor has cleared from your body.
Taking phentermine together with other diet medications such as fenfluramine (Phen-Fen) or dexfenfluramine (Redux) can cause a rare fatal lung disorder called pulmonary hypertension. Do not take phentermine with any other diet medications without your doctor's advice.
You should not take phentermine if you are allergic to it, or if you have:
coronary artery disease (hardening of the arteries);
heart disease;
severe or uncontrolled high blood pressure;
overactive thyroid;
glaucoma;
if you have a history of drug or alcohol abuse; o
if you are allergic to other diet pills, amphetamines, stimulants, or cold medications.
If you have any of these other conditions, you may need a phentermine dose adjustment or special tests:
high blood pressure;
diabetes; or
a thyroid disorder.
FDA pregnancy category C. It is not known whether phentermine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Phentermine can pass into breast milk and may harm a nursing baby. You should not breast-feed while taking phentermine. Do not give this medication to a child younger than 16 years old. Phentermine may be habit-forming and should be used only by the person it was prescribed for. Never share phentermine with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it.
How should I take Obenix (phentermine)?
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
It is best to take phentermine on an empty stomach before breakfast or within 2 hours after breakfast.
To prevent sleep problems, take this medication early in the day, no later than 6:00 pm.
Talk with your doctor if you have increased hunger or if you otherwise think the medication is not working properly. Taking more of this medication will not make it more effective and can cause serious, life-threatening side effects.
Phentermine should be taken only for a short time, such as a few weeks.
Do not stop taking phentermine suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using phentermine. Store at room temperature away from moisture and heat. Keep track of the amount of medicine used from each new bottle. Phentermine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.
What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of phentermine can be fatal.
Overdose symptoms may include confusion, hallucinations, panic, feeling hostile or aggressive, nausea, vomiting, diarrhea, stomach cramps, irregular heartbeat, rapid breathing, overactive reflexes, confusion, hallucinations, seizure (convulsions), feeling light-headed, or fainting.
What should I avoid while taking Obenix (phentermine)?
Drinking alcohol can increase certain side effects of phentermine. Phentermine may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.
Obenix (phentermine) side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:
feeling short of breath, even with mild exertion;
chest pain, feeling like you might pass out;
swelling in your ankles or feet;
pounding heartbeats or fluttering in your chest;
confusion or irritability, unusual thoughts or behavior;
feelings of extreme happiness or sadness; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).
Less serious side effects may include:
feeling restless or hyperactive;
headache, dizziness, tremors;
sleep problems (insomnia);
dry mouth or an unpleasant taste in your mouth;
diarrhea or constipation, upset stomach; or
increased or decreased interest in sex, impotence.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Obenix (phentermine)?
Tell your doctor about all other medicines you use, especially:
blood pressure medications;
insulin or oral diabetes medication;
guanethidine (Ismelin); or
an antidepressant such as citalopram (Celexa), fluoxetine (Prozac, Sarafem, Symbyax), paroxetine (Paxil), sertraline (Zoloft), and others.
This list is not complete and other drugs may interact with phentermine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
More Obenix resources
- Obenix Side Effects (in more detail)
- Obenix Use in Pregnancy & Breastfeeding
- Drug Images
- Obenix Drug Interactions
- Obenix Support Group
- 0 Reviews for Obenix - Add your own review/rating
- Phentermine Prescribing Information (FDA)
- Phentermine Monograph (AHFS DI)
- Adipex-P MedFacts Consumer Leaflet (Wolters Kluwer)
- Adipex-P Prescribing Information (FDA)
- Fastin Advanced Consumer (Micromedex) - Includes Dosage Information
- Ionamin MedFacts Consumer Leaflet (Wolters Kluwer)
- Ionamin Prescribing Information (FDA)
Compare Obenix with other medications
- Obesity
- Weight Loss
Where can I get more information?
- Your pharmacist can provide more information about phentermine.
See also: Obenix side effects (in more detail)
Saturday, 7 August 2010
Calciodie
Calciodie may be available in the countries listed below.
Ingredient matches for Calciodie
Calcium Carbonate
Calcium Carbonate is reported as an ingredient of Calciodie in the following countries:
- Italy
International Drug Name Search
OptiPranolol
metipranolol
Dosage Form: ophthalmic solution
OptiPranolol
metipranolol ophthalmic solution 0.3%
OptiPranolol Description
OptiPranolol® (metipranolol ophthalmic solution) 0.3% contains metipranolol, a non-selective beta-adrenergic receptor blocking agent. Metipranolol is a white, odorless, crystalline powder.
The chemical name of metipranolol is (±)-1-(4-Hydroxy-2, 3, 5-trimethylphenoxy)-3-(isopropylamino)-2-propanol-4-acetate.
The chemical structure of metipranolol is:
C17H27NO4
Mol. Wt. 309.40
Each mL of OptiPranolol® contains 3 mg of metipranolol. INACTIVES: Povidone, Glycerin, Hydrochloric Acid, Sodium Chloride, Edetate Disodium, and Purified Water. Sodium Hydroxide and/or Hydrochloric Acid may be added to adjust pH. The product is produced at pH 5.0-5.8 and osmolality 265 to 330 mOsmol/kg. PRESERVATIVE ADDED: Benzalkonium Chloride 0.004%.
OptiPranolol - Clinical Pharmacology
Metipranolol blocks beta1 and beta2 (non-selective) adrenergic receptors. It does not have significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity.
Orally administered beta-adrenergic blocking agents reduce cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac output.
Beta-adrenergic receptor blockade in the bronchi and bronchioles may result in significantly increased airway resistance from unopposed parasympathetic activity. Such an effect is potentially dangerous in patients with asthma or other bronchospastic conditions (see CONTRAINDICATIONS and WARNINGS).
OptiPranolol Ophthalmic Solution, when applied topically in the eye, has the action of reducing elevated as well as normal intraocular pressure (IOP), whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss.
The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.
The primary mechanism of the ocular hypotensive action of metipranolol is most likely due to a reduction in aqueous humor production. A slight increase in outflow may be an additional mechanism. OptiPranolol Ophthalmic Solution reduces IOP with little or no effect on pupil size or accommodation.
In controlled studies of patients with intraocular pressure greater than 24 mmHg at baseline, OptiPranolol Ophthalmic Solution reduced the average intraocular pressure approximately 20-26%.
The onset of action of OptiPranolol Ophthalmic Solution, as measured by a reduction in intraocular pressure, occurs within 30 minutes after a single administration. The maximum effect occurs at about 2 hours. A reduction in intraocular pressure can be demonstrated 24 hours after a single dose.
Clinical studies in patients with glaucoma treated for up to two years indicate that an intraocular pressure lowering effect is maintained.
ANIMAL PHARMACOLOGY
In rabbits administered metipranolol in one eye at 2 to 4 fold increased concentrations, multi-focal interstitial nephritis was observed in male animals, and lympho-hystiocytic and heterophilic interstitial pneumonia was observed in female animals. The clinical relevance of these findings is unknown.
Indications and Usage for OptiPranolol
OptiPranolol Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
Contraindications
Hypersensitivity to any component of this product.
OptiPranolol Ophthalmic Solution is contraindicated in patients with bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease; symptomatic sinus bradycardia; greater than a first degree atrioventricular block; cardiogenic shock; or overt cardiac failure.
Warnings
As with other topically applied ophthalmic drugs, this drug may be absorbed systemically. Thus, the same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely, death in association with cardiac failure, have been reported following topical application of beta-adrenergic blocking agents (see CONTRAINDICATIONS).
Since OptiPranolol Ophthalmic Solution had a minor effect on heart rate and blood pressure in clinical studies, caution should be observed in treating patients with a history of cardiac failure. Treatment with OptiPranolol Ophthalmic Solution should be discontinued at the first evidence of cardiac failure.
OptiPranolol Ophthalmic Solution, or other beta-blockers, should not, in general, be administered to patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity (see CONTRAINDICATIONS). However, if the drug is necessary in such patients, then it should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta2 receptors.
Precautions
General
Because of potential effects of beta-adrenergic receptor blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with OptiPranolol Ophthalmic Solution, alternative therapy should be considered.
Some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents in patients undergoing elective surgery. If necessary during surgery, the effects of beta-adrenergic receptor blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or levarterenol.
While OptiPranolol Ophthalmic Solution has demonstrated a low potential for systemic effect, it should be used with caution in patients with diabetes (especially labile diabetes) because of possible masking of signs and symptoms of acute hypoglycemia.
Beta-adrenergic receptor blocking agents may mask certain signs and symptoms of hyperthyroidism, and their abrupt withdrawal might precipitate a thyroid storm.
Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness).
Risk of anaphylactic reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
Information for patients
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.
Patients should be advised that OptiPranolol contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following OptiPranolol administration.
Drug interactions
OptiPranolol® Ophthalmic Solution should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade.
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or bradycardia.
Caution should be used in the coadministration of beta-adrenergic receptor blocking agents, such as metipranolol, and oral or intravenous calcium channel antagonists, because of possible precipitation of left ventricular failure, and hypotension. In patients with impaired cardiac function, who are receiving calcium channel antagonists, coadministration should be avoided.
The concomitant use of beta-adrenergic receptor blocking agents with digitalis and calcium channel antagonists may have additive effects, prolonging atrioventricular conduction time.
Caution should be used in patients using concomitant adrenergic psychotropic drugs.
Ocular
In patients with angle-closure glaucoma, the immediate treatment objective is to re-open the angle by constriction of the pupil with a miotic agent.
OptiPranolol Ophthalmic Solution has little or no effect on the pupil, therefore, when it is used to reduce intraocular pressure in angle-closure glaucoma, it should be used only with concomitant administration of a miotic agent.
Carcinogenesis, mutagenesis, impairment of fertility
Lifetime studies with metipranolol have been conducted in mice at oral doses of 5, 50, and 100 mg/kg/day and in rats at oral doses of up to 70 mg/kg/day. Metipranolol demonstrated no carcinogenic effect. In the mouse study, female animals receiving the low, but not the intermediate or high dose, had an increased number of pulmonary adenomas. The significance of this observation is unknown. In a variety of in vitro and in vivo bacterial and mammalian cell assays, metipranolol was nonmutagenic.
Reproduction and fertility studies of metipranolol in rats and mice showed no adverse effect on male fertility at oral doses of up to 50 mg/kg/day, and female fertility at oral doses of up to 25 mg/kg/day.
Pregnancy
Teratogenic effects
Pregnancy Category C:
No drug related effects were reported for the segment II teratology study in fetal rats after administration, during organogenesis, to dams of up to 50 mg/kg/day. OptiPranolol Ophthalmic Solution has been shown to increase fetal resorption, fetal death, and delayed development when administered orally to rabbits at 50 mg/kg/day during organogenesis.
There are no adequate and well-controlled studies in pregnant women. OptiPranolol Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing mothers
It is not known whether OptiPranolol Ophthalmic Solution is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OptiPranolol Ophthalmic Solution is administered to nursing women.
Pediatric use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Adverse Reactions
In clinical trials, the use of OptiPranolol Ophthalmic Solution has been associated with transient local discomfort.
Other ocular adverse reactions, such as abnormal vision, blepharitis, blurred vision, browache, conjunctivitis, edema, eyelid dermatitis, photophobia, tearing, and uveitis have been reported in small numbers of patients.
Other systemic adverse reactions, such as allergic reaction, angina, anxiety, arthritis, asthenia, atrial fibrillation, bradycardia, bronchitis, coughing, depression, dizziness, dyspnea, epistaxis, headache, hypertension, myalgia, myocardial infarct, nausea, nervousness, palpitation, rash, rhinitis, and somnolence have also been reported in small numbers of patients.
Overdosage
No information is available on overdosage of OptiPranolol Ophthalmic Solution in humans. The symptoms which might be expected with an overdose of a systemically administered beta-adrenergic receptor blocking agent are bradycardia, hypotension and acute cardiac failure.
OptiPranolol Dosage and Administration
The recommended dose is one drop of OptiPranolol Ophthalmic Solution in the affected eye(s) twice a day.
If the patient’s IOP is not at a satisfactory level on this regimen, use of more frequent administration or a larger dose of OptiPranolol Ophthalmic Solution is not known to be of benefit. Concomitant therapy to lower intraocular pressure can be instituted.
In clinical trials, OptiPranolol® Ophthalmic Solution was safely used during concomitant therapy with pilocarpine, epinephrine or acetazolamide.
How is OptiPranolol Supplied
OptiPranolol® (metipranolol ophthalmic solution) 0.3% is supplied in a plastic bottle with a controlled drop tip and a yellow plastic screw-top cap as follows:
5 mL: NDC 24208-275-07 - AB40207
10 mL: NDC 24208-275-09 - AB40209
STORAGE
Store between 15° - 30°C (59° - 86°F). Replace cap immediately after use.
DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.
FOR OPHTHALMIC USE ONLY.
Rx only
MANUFACTURER INFORMATION
Bausch & Lomb Incorporated
Tampa, FL 33637
©Bausch & Lomb Incorporated
XO50329
XM10041
Rev. 11/03-91
Principal Display Panel
NDC 24208-275-09
Bausch & Lomb
OptiPranolol
(metipranolol ophthalmic solution)
0.3%
STERILE
Rx only
[icon- eye]
10 mL
| OptiPranolol metipranolol solution/ drops | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA019907 | 12/29/1989 | |
| Labeler - Bausch & Lomb Incorporated (196603781) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Bausch & Lomb Incorporated | 807927397 | MANUFACTURE | |
More OptiPranolol resources
- OptiPranolol Side Effects (in more detail)
- OptiPranolol Dosage
- OptiPranolol Use in Pregnancy & Breastfeeding
- OptiPranolol Drug Interactions
- OptiPranolol Support Group
- 0 Reviews for OptiPranolol - Add your own review/rating
- OptiPranolol Drops MedFacts Consumer Leaflet (Wolters Kluwer)
- OptiPranolol Concise Consumer Information (Cerner Multum)
- Optipranolol Advanced Consumer (Micromedex) - Includes Dosage Information
Compare OptiPranolol with other medications
- Glaucoma, Open Angle
- Intraocular Hypertension
Friday, 6 August 2010
Ichthoseptal
Ichthoseptal may be available in the countries listed below.
Ingredient matches for Ichthoseptal
Chloramphenicol
Chloramphenicol is reported as an ingredient of Ichthoseptal in the following countries:
- Germany
Ichthammol
Ichthammol sodium salt, decolorized (a derivative of Ichthammol) is reported as an ingredient of Ichthoseptal in the following countries:
- Germany
International Drug Name Search
Sunday, 1 August 2010
Conjunctivitis, Bacterial Medications
Definition of Conjunctivitis, Bacterial:
A bacterial infection of a portion of the eye known as the conjunctiva.
Common symptoms include redness of the eyes with a thick, often coloured purulent discharge.
More...
Drugs associated with Conjunctivitis, Bacterial
The following drugs and medications are in some way related to, or used in the treatment of Conjunctivitis, Bacterial. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Learn more about Conjunctivitis, Bacterial
Medical Encyclopedia:
- Conjunctivitis
Drug List:
Tuesday, 27 July 2010
Wilzin
Wilzin may be available in the countries listed below.
UK matches:
- Wilzin 25 mg hard capsules (SPC)
- Wilzin 50 mg hard capsules (SPC)
Ingredient matches for Wilzin
Zinc Acetate
Zinc Acetate is reported as an ingredient of Wilzin in the following countries:
- Austria
- Belgium
- Denmark
- France
- Germany
- Netherlands
- Poland
- Slovakia
- Slovenia
- Spain
- United Kingdom
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Click for further information on drug naming conventions and International Nonproprietary Names.
Subscribe to:
Posts (Atom)